First Responder Technologies
  • First Responder Technologies (WPN) announced a non-brokered private placement for gross proceeds of up to $595,000
  • The company intends to issue up to 7,000,000 units at $0.085 per unit
  • Each unit will consist of one common share and one common share purchase warrant
  • First Responder is a Vancouver B.C. based technology development company
  • First Responder Technologies Inc. (WPN) opened trading at C$0.135 per share

First Responder Technologies (WPN) announced a non-brokered private placement for gross proceeds of up to $595,000.

The company intends to issue up to 7,000,000 units at $0.085 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional share at $0.11 for 24 months from the date of closing.

First Responder may pay finder’s fees for this offering. The company will use the proceeds for general corporate purposes.

Closing of the offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals. All securities issued will be subject to a statutory hold period of four months.

About First Responder Technologies

First Responder is a Vancouver B.C. based technology development company. It commercializes academic and internally developed intellectual property for use in the public safety market.

The company is developing a WiFi-based concealed weapons detection system to protect the perimeter of soft targets, such as theatres, shopping centres, and sports venues.

First Responder Technologies Inc. (WPN) opened trading at C$0.135 per share.


More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.